This is a routine service agreement for a pre-revenue company. The deferred payment and equity conversion clauses signal ongoing cash constraints. Monitor for any future 8-K filings related to share issuance for payment or progress on the digital token platform.
Price Chart
Executive Summary
Raphael Pharmaceutical entered into a 12-month, $180,000 managed AI services agreement with AIcreatesAI for digital transformation, commercialization, and growth operations. The agreement includes a deferred payment arrangement acknowledging Raphael's limited operating cash, an equity conversion option for unpaid fees, and a 2% revenue participation for AIcreatesAI on a future digital token platform. This is a routine service contract for a pre-revenue company, with the deferred payment and equity conversion clauses highlighting significant cash constraints.
Key Financial Metrics
Key Facts
- Raphael entered a 12-month Enterprise AI Transformation and Growth Partnership with AIcreatesAI, effective July 30, 2026.
- The annual managed-services fee is $180,000, payable in monthly installments of $15,000.
- The agreement includes a deferred payment arrangement if Raphael lacks sufficient operating cash, with an option to settle via common stock issuance.
- AIcreatesAI will receive 2% of net profits from a future company-branded digital token platform, separate from the annual fee.
- The agreement was signed by CEO Shlomo Pilo for Raphael and CEO Sholom Stein for AIcreatesAI.
Financial Impact
Annual managed-services fee of $180,000; potential future equity dilution if deferred payments are settled via common stock; AIcreatesAI receives 2% of net profits from a future digital token platform.
Risk Factors
- Deferred payment arrangement and equity conversion option highlight significant cash constraints and potential future dilution.
- The agreement does not guarantee any specific business results, including sales, profitability, or regulatory approval.
- The digital token platform is subject to board approval and applicable law, with no guarantee of launch or profitability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (RAPH) — Batch item 1 | 0001213900-26-096113 |
| Document: ea0304182-8k_raphael.htm | 0001213900-26-096113 |
| Document: 0001213900-26-096113-index-headers.html | 0001213900-26-096113 |
| Document: 0001213900-26-096113-index.html | 0001213900-26-096113 |
| Document: 0001213900-26-096113.txt | 0001213900-26-096113 |
| 8-K Filing (RAPH) — Batch item 6 | 0001213900-26-096113 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 7w ago | 8-K | $1.40 $1.40 | · 0.00% | ▼ −1.18% | $1.51 (+7.86%) |
Jul 17, 2026 14w ago | 8-K | $1.40 $1.40 | · 0.00% | ▼ −4.45% | $1.51 (+7.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers